Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Feb;153(3):459-67.
doi: 10.1038/sj.bjp.0707588. Epub 2007 Dec 3.

Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation

P-A Paquette  1 , D Duguay, R El-Ayoubi, A Menaouar, B Danalache, J Gutkowska, D DeBlois, S Mukaddam-Daher
Affiliations

Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation

P-A Paquette et al. Br J Pharmacol. 2008 Feb.

Abstract

Background and purpose: Left ventricular hypertrophy (LVH) is a maladaptive process associated with increased cardiovascular risk. Regression of LVH is associated with reduced complications of hypertension. Moxonidine is an antihypertensive imidazoline compound that reduces blood pressure primarily by central inhibition of sympathetic outflow and by direct actions on the heart to release atrial natriuretic peptide, a vasodilator and an antihypertrophic cardiac hormone. This study investigated the effect of moxonidine on LVH and the mechanisms involved in this effect.

Experimental approach: Spontaneously hypertensive rats were treated with several doses of moxonidine (s.c.) over 4 weeks. Blood pressure and heart rate were continuously monitored by telemetry. Body weight and water and food intake were measured weekly. Measurements also included left ventricular mass, DNA content, synthesis, fragmentation, and apoptotic/anti-apoptotic pathway proteins.

Key results: The decrease in mean arterial pressure stabilized at approximately -10 mm Hg after 1 week of treatment and thereafter. Compared to vehicle-treated rats (100%), left ventricular mass was dose- and time-dependently reduced by treatment. This reduction remained significantly lower after normalizing to body weight. Moxonidine reduced left ventricular DNA content and inhibited DNA synthesis. DNA fragmentation transiently, but significantly increased at 1 week of moxonidine treatment and was paralleled by elevated active caspase-3 protein. The highest dose significantly decreased the apoptotic protein Bax and all doses stimulated anti-apoptotic Bcl-2 after 4 weeks of treatment.

Conclusions and implications: These studies implicate the modulation of cardiac DNA dynamics in the control of left ventricular mass by moxonidine in a rat model of hypertension.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The effect of 4 weeks treatment with various concentrations of moxonidine on body weight. *P<0.001 vs basal; **P<0.01 vs corresponding vehicle-treated groups; n=8–23 rats per group.
Figure 2
Figure 2
The effect of 1-, 2- and 4-week treatment with various concentrations of moxonidine on (a) left ventricular mass and (b) left ventricular DNA content, presented as percentage of corresponding vehicle-treated rats (100%). (c) Correlation between percentage decrease in left ventricular mass vs percentage decrease in DNA content in 4-week moxonidine-treated spontaneously hypertensive rat (SHR). *P<0.01 vs corresponding vehicle-treated groups. n=6–8 rats per group.
Figure 3
Figure 3
The effect of 1-, 2- and 4-week treatment with various concentrations of moxonidine on left ventricular 3H-thymidine incorporation, presented as percentage of corresponding vehicle-treated rats (100%). *P<0.04; **P<0.01 vs corresponding vehicle-treated groups; n=3–5 rats per group.
Figure 4
Figure 4
The effect of 1-, 2- and 4-week treatment with various concentrations of moxonidine on left ventricular DNA fragmentation. (a) DNA laddering, n=3–7 rats per group. (b) Cell death detection by ELISA, n=3–6 rats per group. *P<0.01; #P<0.05 vs corresponding vehicle-treated groups. $P<0.05 vs corresponding 100 μg kg−1 h−1 moxonidine-treated group. Data are presented as percentage of vehicle-treated control (100%).
Figure 5
Figure 5
Representative western blot analysis of the effect of 1-, 2- and 4-week treatment with moxonidine on left ventricular Bax and Bcl-2 proteins. Column graph represents Bax/Bcl-2 ratio. *P<0.01 vs corresponding vehicle-treated spontaneously hypertensive rat (SHR); n=5–7 rats per group.
Figure 6
Figure 6
Western blot analysis of the effect of 1-, 2- and 4-week treatment with moxonidine on left ventricular pro- and cleaved caspase-3 protein expression. Column graph represents cleaved to pro-caspase-3 ratio. *P<0.05; **P<0.01 vs vehicle-treated spontaneously hypertensive rat (SHR). n=6–9 rats per group.
See this image and copyright information in PMC

References

    1. Amador N, de Jesus Encarnacion J, Rodriguez L, Tello A, Lopez M, Guizar JM. Relationship between left ventricular mass and heart sympathetic activity in male obese subjects. Arch Med Res. 2004;35:411–415. - PubMed
    1. Amann K, Greber D, Gharehbaghi H, Wiest G, Lange B, Ganten U, et al. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. Stereological studies on myocytes, capillaries, arteries, and cardiac interstitium. Am J Hypertens. 1992;5:76–83. - PubMed
    1. Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A, et al. Myocardial directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817–830. - PubMed
    1. Bobik A, Dilley R, Kanellakis P. Sympatho-adrenal mechanisms regulating cardiovascular hypertrophy in primary hypertension: a role for rilmenidine. J Hypertens. 1998;16:S51–S54. - PubMed
    1. Braz Nogueira J. Regression of left ventricular hypertrophy in hypertension—does it reduce cardiovascular risk. Rev Port Cardiol. 2005;24:1007–1013. - PubMed

Publication types

MeSH terms